FDA accepts Milestone's response on Cardamyst nasal spray, sets new PDUFA date; company raises $52.5 million to support ...

People with hay fever could one day benefit from a first-of-its-kind “molecular shield” that blocks pollen from entering the ...

The Food and Drug Administration (FDA) has accepted for review Milestone’s response to issues raised in a Complete Response Letter (CRL) for etripamil nasal spray (Cardamyst ™ ), an investigational ...

Evoke Pharma's stock soared 168% on Wednesday after the company announced it had received a new U.S. patent that could extend ...

Vaccine experts have developed an antibody that, when applied to the nose, intercepts allergens before they can trigger a ...

New Opportunities will be offering a free “Be Prepared” presentation to assist in identifying and how to respond to an opioid overdose. On July 18 at the Audubon Rec Center Community Room, New Opportu ...

New PDUFA Action Date of December 13, 2025 $75 Million Royalty Purchase Agreement Payment from RTW Extended Through 2025 MONTREAL and CHARLOTTE, N.C., July 11, 2025 (GLOBE NEWSWIRE) -- Milestone® ...

A mid-stage trial of BPL‑003 nasal spray shows promising results for treatment-resistant depression, igniting biotech ...

ARS Pharmaceuticals' Neffy, an epinephrine nasal spray, is poised as a game-changer for emergency allergies, driving growth.

A new study shows that oxytocin nasal spray helps mothers with postpartum depression interact more positively with their babies.

A psychedelic nasal spray requiring a much shorter period of clinical supervision has shown promise against ...